The FDA has called for the addition of a Boxed Warning alerting clinicians and patients of an increased risk of cardiovascular death with the use of a drug used for the treatment of gout.
The FDA has called for the addition of a Boxed Warning alerting clinicians and patients of an increased risk of cardiovascular death with the use of a drug used for the treatment of gout.
After clinical trials demonstrated its safety and efficacy, the FDA approved a new treatment that is the first to combine standard care with a new therapy for adult patients with hyperuricemia associated...
